Skip to main content
Home
Zeitschriften
Zeitungen
Podcast
Gesundheitspolitik
Praxis
Allerlei
Jobs
Fachgebiete
Allgemeinmedizin Anästhesiologie & Intensivmedizin Apotheke Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kinder & Jugendheilkunde Neurologie & Psychiatrie Orthopädie & Unfallchirurgie Pflege Urologie Zahnmedizin
Subfächer Innere Medizin
Diabetologie Gastroenterologie Infektiologie Kardiologie Onkologie und Hämatologie Pneumologie Rheumatologie
Fortbildungen
Überblick Fortbildungen DFP-Literaturstudium-Artikel DFP-Webcast Fortbildungen DFP-Podcasts
Erweiterte Suche
Anmelden
nach oben
Wiener Medizinische Wochenschrift
Erschienen in:

01.01.2015 | themenschwerpunkt

Biologika bei SLE

verfasst von: Dr. med. univ. Thomas Karonitsch, Prof. Dr. med. univ. Martin Aringer

Erschienen in: Wiener Medizinische Wochenschrift | Ausgabe 1-2/2015

Einloggen, um Zugang zu erhalten

Zusammenfassung

Bei allen häufigeren rheumatischen Erkrankungen sind Biologika seit vielen Jahren nicht mehr wegzudenken. In der Behandlung des systemischen Lupus erythematodes (SLE) wird seit zehn Jahren die B-Zell-Depletion bei meist schwerst kranken SLE Patienten als Off label-Therapie eingesetzt. Die ersten kontrollierten Rituximab-Studien bleiben jedoch, wie viele andere klinische Prüfungen beim SLE, wider Erwarten negativ, und neue klinische Prüfungen mit einem besseren Protokoll versuchen derzeit die Frage endgültig zu klären. Erst 2012 begann mit der Zulassung von Belimumab die Ära der zugelassenen Biologikatherapie. Dieser Anti-Blys/BAFF-Antikörper verhindert Schübe, spart Glukokortikoide ein und verbessert deutlich die Lebensqualität, zum Teil durch drastische Verbesserung der durch Immunkomplexe bedingten ausgeprägten Abgeschlagenheit. Vielversprechende Daten zu mehreren anderen Ansätzen lassen hoffen, dass weitere Biologika den Einzug in den klinischen Alltag finden werden.
Vorheriger Artikel Biological agents in psoriatic arthritis
Literatur
1.
Furst DE, Keystone EC, Braun J, Breedveld FC, Burmester GR, De BF, et al. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2011. Ann Rheum Dis. 2012;71(Suppl 2):i2–45.CrossRefPubMed
2.
Furie RA, Petri MA, Wallace DJ, Ginzler EM, Merrill JT, Stohl W, et al. Novel evidence-based systemic lupus erythematosus responder index. Arthritis Rheum. 2009;61(9):1143–51.CrossRefPubMedCentralPubMed
3.
Navarra SV, Guzman RM, Gallacher AE, Hall S, Levy RA, Jimenez RE, et al. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Lancet. 2011;377(9767):721–31.CrossRefPubMed
4.
Furie R, Petri M, Zamani O, Cervera R, Wallace DJ, Tegzova D, et al. A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum. 2011;63(12):3918–30.CrossRefPubMed
5.
Manzi S, Sanchez-Guerrero J, Merrill JT, Furie R, Gladman D, Navarra SV, et al. Effects of belimumab, a B lymphocyte stimulator-specific inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus: combined results from two phase III trials. Ann Rheum Dis. 2012;71(11):1833–8.CrossRefPubMedCentralPubMed
6.
Fischer-Betz R, Schneider M. [Recommendation for use of belimumab for systemic lupus erythematosus]. Z Rheumatol. 2013;72(5):462–7.CrossRefPubMed
7.
Strand V, Cooper S, Zhong ZJ, Dennis G. Responders in the phase 3 belimumab clinical trials in patients with systemic lupus erythematosus reported improvements in fatigue and health-related quality of life at week 52. Arthritis Rheum. 2011;63(Supplement 10):535–6.
8.
Bauernfeind B, Aringer M, Prodinger B, Kirchberger I, Machold K, Smolen J, et al. Identification of relevant concepts of functioning in daily life in people with systemic lupus erythematosus: A patient Delphi exercise. Arthritis Rheum. 2009;61(1):21–8.CrossRefPubMed
9.
Looney RJ, Anolik JH, Campbell D, Felgar RE, Young F, Arend LJ, et al. B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I/II dose-escalation trial of rituximab. Arthritis Rheum. 2004;50(8):2580–9.CrossRefPubMed
10.
Leandro MJ, Ehrenstein MR, Edwards JCW, Manson J, Cambridge G, Isenberg DA. Treatment of refractory lupus nephritis with B lymphocyte depletion. Arthritis Rheum. 2003;48(9):S 378.
11.
Bertsias GK, Tektonidou M, Amoura Z, Aringer M, Bajema I, Berden JH, et al. Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. Ann Rheum Dis. 2012;71(11):1771–82.CrossRefPubMedCentralPubMed
12.
Aringer M, Burkhardt H, Burmester GR, Fischer-Betz R, Fleck M, Graninger W, et al. Current state of evidence on ‚off-label‘ therapeutic options for systemic lupus erythematosus, including biological immunosuppressive agents, in Germany, Austria and Switzerland–a consensus report. Lupus. 2012;21(4):386–401.CrossRefPubMed
13.
Lu TY, Ng KP, Cambridge G, Leandro MJ, Edwards JC, Ehrenstein M, et al. A retrospective seven-year analysis of the use of B cell depletion therapy in systemic lupus erythematosus at University College London Hospital: the first fifty patients. Arthritis Rheum. 2009;61(4):482–7.CrossRefPubMed
14.
Terrier B, Amoura Z, Ravaud P, Hachulla E, Jouenne R, Combe B, et al. Safety and efficacy of rituximab in systemic lupus erythematosus: results from 136 patients from the French AutoImmunity and Rituximab registry. Arthritis Rheum. 2010;62(8):2458–66.CrossRefPubMed
15.
Witt M, Grunke M, Proft F, Baeuerle M, Aringer M, Burmester G, et al. Clinical outcomes and safety of rituximab treatment for patients with systemic lupus erythematosus (SLE) – results from a nationwide cohort in Germany (GRAID). Lupus. 2013;22(11):1142–9.CrossRefPubMed
16.
Ng KP, Manson JJ, Rahman A, Isenberg DA. Association of antinucleosome antibodies with disease flare in serologically active clinically quiescent patients with systemic lupus erythematosus. Arthritis Rheum. 2006;55(6):900–4.CrossRefPubMed
17.
Merrill JT, Neuwelt CM, Wallace DJ, Shanahan JC, Latinis KM, Oates JC, et al. Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum. 2010;62(1):222–33.
18.
Rovin BH, Furie R, Latinis K, Looney RJ, Fervenza FC, Sanchez-Guerrero J, et al. Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: The lupus nephritis assessment with rituximab (LUNAR) study. Arthritis Rheum. 2012;64(4):1215–26.CrossRefPubMed
19.
Carson KR, Focosi D, Major EO, Petrini M, Richey EA, West DP, et al. Monoclonal antibody-associated progressive multifocal leucoencephalopathy in patients treated with rituximab, natalizumab, and efalizumab: a Review from the Research on Adverse Drug Events and Reports (RADAR) Project. Lancet Oncol. 2009;10(8):816–24.CrossRefPubMed
20.
Daikh DI, Finck BK, Linsley PS, Hollenbaugh D, Wofsy D. Long-term inhibition of murine lupus by brief simultaneous blockade of the B7/CD28 and CD40/gp39 costimulation pathways. J Immunol. 1997;159(7):3104–8.PubMed
21.
Merrill JT, Burgos-Vargas R, Westhovens R, Chalmers A, D’Cruz D, Wallace DJ, et al. The efficacy and safety of abatacept in patients with non-life-threatening manifestations of systemic lupus erythematosus: results of a twelve-month, multicenter, exploratory, phase IIb, randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2010;62(10):3077–87.CrossRefPubMed
22.
Furie R, Nicholls K, Cheng TT, Houssiau F, Burgos-Vargas R, Chen SL, et al. Efficacy and safety of abatacept in lupus nephritis: a twelve-month, randomized, double-blind study. Arthritis Rheumatol. 2014;66(2):379–89.CrossRefPubMed
23.
Wofsy D, Hillson JL, Diamond B. Abatacept for lupus nephritis: alternative definitions of complete response support conflicting conclusions. Arthritis Rheum. 2012;64(11):3660–5.CrossRefPubMed
24.
Wofsy DA, Askanase A, Cagnoli PC, Chatham WW, Contreras G, Dall’Era M, et al. Treatment of lupus nephritis with abatacept plus low-dose pulse cyclophosphamide followed by azathioprine (the Euro-Lupus regimen): twenty-four week data from a double-blind controlled trial. Arthritis Rheum. 2013;65(Supplement 10):884–5.
25.
Ostendorf B, Iking-Konert C, Kurz K, Jung G, Sander O, Schneider M. Preliminary results of safety and efficacy of the interleukin 1 receptor antagonist anakinra in patients with severe lupus arthritis. Ann Rheum Dis. 2005;64(4):630–3.CrossRefPubMedCentralPubMed
26.
Moosig F, Zeuner R, Renk C, Schroder JO. IL-1RA in refractory systemic lupus erythematosus. Lupus. 2004;13(8):605–6.CrossRefPubMed
27.
28.
Illei GG, Shirota Y, Yarboro CH, Daruwalla J, Tackey E, Takada K, et al. Tocilizumab in systemic lupus erythematosus: Data on safety, preliminary efficacy, and impact on circulating plasma cells from an open-label phase I dosage-escalation study. Arthritis Rheum. 2010;62(2):542–52.CrossRefPubMedCentralPubMed
29.
Aringer M, Graninger WB, Steiner G, Smolen JS. Safety and efficacy of TNFï blockade in systemic lupus erythematosus – an open label study. Arthritis Rheum. 2004;50(10):3161–9.30.CrossRefPubMed
30.
Aringer M, Steiner G, Graninger WB, Hofler E, Steiner CW, Smolen JS. Effects of short-term infliximab therapy on autoantibodies in systemic lupus erythematosus. Arthritis Rheum. 2007;56(1):274–9.CrossRefPubMed
31.
Aringer M, Houssiau F, Gordon C, Graninger WB, Voll RE, Rath E, et al. Adverse events and efficacy of TNF-alpha blockade with infliximab in patients with systemic lupus erythematosus: long-term follow-up of 13 patients. Rheumatology (Oxford). 2009;48(11):1451–4.CrossRef
32.
Aringer M, Graninger WB, Steiner G, Smolen JS. Safety and efficacy of tumor necrosis factor alpha blockade in systemic lupus erythematosus: An open-label study. Arthritis Rheum. 2004;50(10):3161–9.CrossRefPubMed
33.
Gunther C, Aringer M, Lochno M, Kammerer E, Bauer A, Wozel G, et al. TNF-alpha Blockade with Infliximab in a Patient with Lupus Erythematosus Profundus. Acta Derm Venereol. 2011;92:401–3. (10-1262).CrossRef
34.
Aringer M, Smolen JS. Therapeutic blockade of TNF in patients with SLE-promising or crazy? Autoimmun Rev. 2012;11(5):321–5.CrossRefPubMed
35.
Petri M, Wallace DJ, Spindler A, Chindalore V, Kalunian K, Mysler E, et al. Sifalimumab, a human anti-interferon-alpha monoclonal antibody, in systemic lupus erythematosus: a phase I randomized, controlled, dose-escalation study. Arthritis Rheum. 2013;65(4):1011–21.CrossRefPubMedCentralPubMed
36.
Merrill JT, Wallace DJ, Petri M, Kirou KA, Yao Y, White WI, et al. Safety profile and clinical activity of sifalimumab, a fully human anti-interferon alpha monoclonal antibody, in systemic lupus erythematosus: a phase I, multicentre, double-blind randomised study. Ann Rheum Dis. 2011;70(11):1905–13.CrossRefPubMed
37.
McBride JM, Jiang J, Abbas AR, Morimoto A, Li J, Maciuca R, et al. Safety and pharmacodynamics of rontalizumab in patients with systemic lupus erythematosus: results of a phase I, placebo-controlled, double-blind, dose-escalation study. Arthritis Rheum. 2012;64(11):3666–76.CrossRefPubMed
38.
Rossi EA, Goldenberg DM, Michel R, Rossi DL, Wallace DJ, Chang CH. Trogocytosis of multiple B-cell surface markers by CD22 targeting with epratuzumab. Blood. 2013; 122(17):3020–9.CrossRefPubMed
39.
Wallace DJ, Gordon C, Strand V, Hobbs K, Petri M, Kalunian K, et al. Efficacy and safety of epratuzumab in patients with moderate/severe flaring systemic lupus erythematosus: results from two randomized, double-blind, placebo-controlled, multicentre studies (ALLEVIATE) and follow-up. Rheumatology (Oxford). 2013;52(7):1313–22.CrossRef
40.
Strand V, Petri M, Kalunian K, Gordon C, Wallace DJ, Hobbs K, et al. Epratuzumab for patients with moderate to severe flaring SLE: health-related quality of life outcomes and corticosteroid use in the randomized controlled ALLEVIATE trials and extension study SL0006. Rheumatology (Oxford). 2014;53(3):502–11.CrossRef
41.
Neubert K, Meister S, Moser K, Weisel F, Maseda D, Amann K, et al. The proteasome inhibitor bortezomib depletes plasma cells and protects mice with lupus-like disease from nephritis. Nat Med. 2008;14(7):748–55.CrossRefPubMed
Metadaten
Titel
Biologika bei SLE
verfasst von
Dr. med. univ. Thomas Karonitsch
Prof. Dr. med. univ. Martin Aringer
Publikationsdatum
01.01.2015
Verlag
Springer Vienna
Erschienen in
Wiener Medizinische Wochenschrift / Ausgabe 1-2/2015
Print ISSN: 0043-5341
Elektronische ISSN: 1563-258X
DOI
https://doi.org/10.1007/s10354-014-0322-9

Weitere Artikel der Ausgabe 1-2/2015

Biological agents in psoriatic arthritis

  • main topic

Biologicals and how they revolutionized rheumatology

  • editorial

Anti-TNFs in axial spondyloarthritis

  • main topic

Efficacy and safety of rituximab in rheumatic diseases

  • main topic

Anti-TNF in rheumatoid arthritis: an overview

  • main topic

Blockade of co-stimulation in chronic inflammatory diseases

  • main topic